CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $191.54M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -1.16: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
191.54MUSDvs all stocks (USD)
Revenue (TTM)
36.49MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.27xvs all stocks
52-Week Change
0.00%vs all stocks
Market Capitalization
191.54MUSDvs all stocks (USD)
Enterprise Value
84.62MUSDvs all stocks (USD)
Forward P/E
-2.03xvs Biotechnology peers
Price to Sales (TTM)
5.25xvs Biotechnology peers
Price to Book (MRQ)
1.10xvs Biotechnology peers
Enterprise to Revenue
2.32xvs Biotechnology peers
Enterprise to EBITDA
-0.7060xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1167.37%vs Biotechnology peers
Return on Assets (TTM)
-27.05%vs Biotechnology peers
Return on Equity (TTM)
-52.26%vs Biotechnology peers
Revenue (TTM)
36.49MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.6190USDUpdated Jul 19, 2026Quarterly Revenue Growth
-59.90%vs Biotechnology peers
Gross Profit (TTM)
-88.86MUSDvs all stocks (USD)
EBITDA (TTM)
-119.94MUSDvs all stocks (USD)
Net Income (TTM)
-116.64MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-59.94%vs Biotechnology peers
Operating Cash Flow (TTM)
-127.99MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-80.83MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
40.37MUSDFY2025 · Dec 31, 2025Operating Income
-131.84MUSDvs all stocks (USD)
Pre-tax Income
-119.58MUSDFY2025 · Dec 31, 2025Income Tax Expense
144.00KUSDFY2025 · Dec 31, 2025Net Income
-119.72MUSDFY2025 · Dec 31, 2025EBIT
-131.84MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-127.78MUSDFY2025 · Dec 31, 2025Research & Development
134.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
37.54MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-119.72MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-130.75MUSDFY2025 · Dec 31, 2025Free Cash Flow
-133.35MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
68.04MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-119.72MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.06MUSDFY2025 · Dec 31, 2025Stock-based Compensation
14.79MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
268.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.02MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-31.16MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.60MUSDFY2025 · Dec 31, 2025Purchase of Investments
-133.93MUSDFY2025 · Dec 31, 2025Sale of Investments
261.97MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
125.45MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
60.31MSharesUpdated Jul 19, 2026Float Shares
44.22MSharesUpdated Jul 19, 2026Shares Short
3.57MSharesUpdated Jul 19, 2026Short Ratio
5.93daysvs all stocks
Short % of Shares Outstanding
6.95%vs all stocks
% Held by Insiders
15.14%vs all stocks
% Held by Institutions
56.28%vs all stocks
Total Cash (MRQ)
141.48MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.34USDUpdated Jul 19, 2026Total Debt (MRQ)
34.57MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1990xvs Biotechnology peers
Current Ratio (MRQ)
8.42xvs Biotechnology peers
Book Value per Share (MRQ)
2.88USDUpdated Jul 19, 2026Total Assets
252.28MUSDvs all stocks (USD)
Total Current Assets
202.69MUSDFY2025 · Dec 31, 2025Total Liabilities
56.20MUSDFY2025 · Dec 31, 2025Total Non-current Assets
49.59MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
29.66MUSDFY2025 · Dec 31, 2025Total Current Liabilities
26.54MUSDFY2025 · Dec 31, 2025Cash
14.14MUSDFY2025 · Dec 31, 2025Cash Equivalents
51.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
65.30MUSDFY2025 · Dec 31, 2025Other Short-term Investments
131.15MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.76MUSDFY2025 · Dec 31, 2025Accounts Payable
5.01MUSDFY2025 · Dec 31, 2025Short-term Debt
7.84MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.59MUSDFY2025 · Dec 31, 2025Long-term Debt
28.66MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
59.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-445.90MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
196.08MUSDvs all stocks (USD)
52-Week Low
2.88USDUpdated Jul 19, 202652-Week High
5.55USDUpdated Jul 19, 202652-Week Change
0.00%vs all stocks
Beta
1.27xvs all stocks
50-Day MA
3.65USDUpdated Jul 19, 2026200-Day MA
4.02USDUpdated Jul 19, 2026Avg 10-Day Volume
846.23KSharesUpdated Jul 19, 2026Avg 30-Day Volume
708.39KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.98USDUpdated Jul 19, 2026Other Income / Expense
1.65MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 8.42Altman Z-Score: -1.16
Financial Health
Altman Z-Score -1.16: distress zoneCritical
Altman Z-Score: -1.16
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $191.54M, lower than 95% of all stocks globallySignificant
Market cap (USD): 191,535,479Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Tonix Pharmaceuticals Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Rightongene Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking